在这样的大背景下，百奥赛图（02315.HK）凭借"双业务线"的布局脱颖而出，成为行业内极具代表性 的"高技术壁垒型产品公司"。 近年来，创新药已成为我国战略性新兴产业的重点发展方向。2025年8月20日，国务院总理李强在北京 调研生物医药产业发展，强调加大科技创新与政策支持，推动生物医药产业升级，并召开座谈会部署创 新药发展重点工作。 回看2024年政府工作报告首次将"创新药"纳入新兴产业重点领域，国务院又出台了《全链条支持创新药 发展实施方案》，明确在研发、临床、注册、支付等环节形成全链条支持体系。党的二十届三中全会更 是提出要健全创新药和医疗器械发展的长效机制，释放出坚定的政策信号。 这背后体现的，是国家从人民健康和产业自主出发的前瞻布局。健康中国战略要求更多满足肿瘤、自 免、罕见病等重大疾病的未被满足医疗需求，而在全球医药产业格局中，创新药也正在成为衡量一国综 合实力和国际竞争力的重要标志。 从"仿制跟随"到"自主创新"，短短十余年间，中国创新药产业经历了跨越式发展。在研发数量上，我国 在研新药数量已跃居全球第二；在产业规模上，一批本土企业通过自主平台和国际合作加速崛起，成为 全球新药版图中不可忽视的 ...

（於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 董事會會議召開日期 百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈，董事會會議將於2025年8月28日（星期四）舉行，藉以（其中包括）(i) 考慮及批准本公司及其附屬公司截至2025年6月30日止六個月的中期業績及其發 佈，以及(ii)考慮派發中期股息（如有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 百奧賽圖（北京）醫藥科技股份有限公司 董事長、首席執行官兼執行董事 沈月雷 香港，2025年8月18日 於本公告日期，董事會包括董事長、首席執行官兼執行董事沈月雷博士、執行董 事倪健博士及張海超博士；非執行董事魏義良先生、周可祥博士及張蕾娣女士； 獨立非執行董事華風茂先生、喻長遠博士及梁曉燕女士。 承董 ...

Core Viewpoint - The strategic partnership between Biocytogen and Megvii Technology aims to enhance the digital and intelligent upgrade of fully human antibody research and production, leveraging their respective strengths in technology and automation to drive high-quality development in the biopharmaceutical industry [1][4][5]. Company Overview - Biocytogen is an international biotechnology company focused on innovative technology-driven drug development, with a comprehensive R&D platform covering target discovery, fully human antibody sequence development, preclinical evaluation, and collaborative transformation [3][10]. - The company has established a large-scale development system for antibodies through its "Thousand Mice, Ten Thousand Antibodies" program, which encompasses over a thousand potential drug targets and a library of over one million fully human antibody sequences [3][10]. - Megvii Technology is a leading provider of autonomous agents in the field of robotics, dedicated to offering comprehensive solutions for smart laboratories and intelligent manufacturing scenarios [10][11]. Strategic Cooperation Details - The collaboration focuses on integrating Biocytogen's technical expertise in antibody development with Megvii's innovative automation capabilities to create an intelligent upgrade system for antibody discovery, preparation, and screening [4][5]. - The partnership aims to optimize research labor input through a multi-agent solution, achieving automation at a scale exceeding one million, thereby enhancing the efficiency and precision of antibody preparation [4][5]. - The LabillionTM data intelligence system will facilitate the efficient integration, real-time analysis, and deep correlation of sequence and functional data generated from high-throughput screening [4][5]. Future Implications - The collaboration is expected to accelerate the innovation process of antibody drugs and explore new models driven by AI and automation, contributing to higher quality development in the biopharmaceutical industry [5][7]. - The integration of Megvii's autonomous intelligent agents with Biocytogen's advanced platforms is anticipated to address core challenges in large-scale antibody discovery and screening, setting a benchmark for the application of AI in the biopharmaceutical sector [7][9].

Core Viewpoint - The company Baiaosaitu (2315.HK) has seen a significant increase in stock price, reaching a new high since October 2022, following positive revenue and profit forecasts for the first half of 2025 [1] Financial Performance - The company expects revenue for the first half of 2025 to be approximately 616 million to 626 million yuan, representing a year-on-year increase of about 50.1% to 52.5% [1] - The projected net profit is estimated to be between 42.7 million to 52.7 million yuan, indicating a turnaround from previous losses [1] Research and Development - The anticipated research and development expenses are expected to be around 206.1 million to 216.1 million yuan, reflecting a year-on-year increase of approximately 27.5% to 33.6% [1]

Core Viewpoint - The innovative pharmaceutical sector has emerged as the "most shining track" in the capital market for the first half of 2025, with the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index achieving a year-to-date increase of 97.01%, marking the highest half-year growth since 2018 [1] Group 1: Company Performance - By the first half of 2025, the company reported revenue exceeding RMB 6 billion, a year-on-year increase of over 50%, and net profit ranging from RMB 42.7 million to RMB 52.7 million, marking a continuous profit validation [1][3] - The company's stock price surged by 209.88% year-to-date, outperforming both the Hang Seng Healthcare Index and the Hang Seng Index [1] Group 2: Strategic Transformation - The company has transitioned its revenue structure from "service infusion" to "product self-sustenance," indicating a successful shift towards high-value products and validating the commercial viability of its technology [3] - The company has established a global presence, enhancing its local service capabilities through the expansion of its Boston laboratory and securing collaborations with top 10 multinational pharmaceutical companies [4] Group 3: Operational Efficiency - The company increased its R&D expenditure to approximately RMB 206.1 million to RMB 216.1 million, a year-on-year increase of about 30%, while optimizing its management structure and digitalizing production processes to enhance operational efficiency [5] - The company achieved net profit for two consecutive reporting periods, indicating the establishment of a commercial flywheel effect from R&D investment to product revenue and profit accumulation [5] Group 4: Market Opportunities - Recent policy measures from the National Healthcare Security Administration and the National Health Commission support the high-quality development of innovative drugs, creating a favorable environment for companies like the subject firm [6] - The capital market's evaluation logic for innovative pharmaceutical companies has fundamentally changed, with a shift from "story-driven" to "performance-driven" valuation, enhancing confidence in profitability [7] Group 5: Globalization and Future Growth - The company is positioned as a significant contributor to the global pharmaceutical pipeline, particularly in the ADC (antibody-drug conjugate) field, and ranks among the top three in terms of outbound licensing transactions [8] - The company's unique technology platforms and innovative antibody assets are expected to establish it as a "technical arms dealer" in the global pharmaceutical landscape, potentially leading to a dual growth trajectory [8] Conclusion - The company is poised for a significant transformation from a follower to a leader in the global innovative drug sector, with its recent profitability breakthrough marking just the beginning of its growth journey [9][10]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百奧賽圖(北京)醫藥科技股份有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02315 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 110,781,920 | RMB | | 1 RMB | | 110,781,920 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 110,781,920 | RMB | | 1 RMB | | 110,781,920 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 截至2025年6月30日止六個月業績快報 本公告乃由百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）根據香港法例第 571章證券及期貨條例第XIVA部項下內幕消息條文（定義見香港聯合交易所有限 公司證券上市規則（「上市規則」））及上市規則第13.09條而作出。 本公告所載本公司及其附屬公司（統稱「本集團」）截至2025年6月30日止六個月的 主要財務數據為根據國際財務報告準則所做之初步財務數據，未經本公司核數師 審計，因此本公告所述之財務數據與本集團截至2025年6月30日止六個月中期業 績公告中披露的數據可能存在差異，最終中期數據以後者披露的數據為準，謹此 提請投資者注意投資風險。 I. 本期業績預告情 ...

Core Viewpoint - The stock of Baiaosaitu-B (02315) surged over 10% following the announcement of a global licensing agreement for antibody molecules with BeiGene, indicating strong market confidence in the company's growth prospects and collaboration with established partners [1] Company Developments - Baiaosaitu has entered into a global licensing agreement with BeiGene, which includes an upfront payment and potential milestone payments based on development and commercialization, as well as royalties based on net sales [1] - The collaboration builds on an existing relationship where BeiGene had previously obtained a license for Baiaosaitu's RenMice fully human antibody platform, reflecting a deepening partnership [1] Financial Performance - Dongwu Securities reported that Baiaosaitu's operational performance in the first half of the year exceeded expectations, with significant growth in business development (BD) activities [1] - The company is expected to achieve over 40% growth in its antibody BD business and maintain over 40% growth in animal models, with preclinical CRO growth nearing 60%, leading to an overall revenue growth exceeding 40% [1]

Core Viewpoint - 百奥赛图-B (02315) has seen a significant increase in stock price following the announcement of a global licensing agreement with BeiGene for antibody molecules, indicating strong market confidence in the company's growth prospects [1] Group 1: Licensing Agreement - 百奥赛图 has entered into a global licensing agreement with BeiGene for antibody molecules, which includes an upfront payment and potential milestone payments based on development and commercialization [1] - The agreement builds on an existing collaboration where BeiGene had previously obtained a license for 百奥赛图's RenMice fully human antibody platform, indicating a deepening partnership [1] Group 2: Financial Performance - 东吴证券 reported that 百奥赛图's operating performance in the first half of the year exceeded expectations, with business development (BD) continuing to grow [1] - The company is expected to achieve over 40% growth in its antibody BD business in the first half of 2025, with animal models maintaining over 40% growth and preclinical CRO growth nearing 60% [1] - Overall revenue growth for 百奥赛图 is projected to exceed 40%, supported by a recovery in domestic industrial clients and a rapid increase in orders [1]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is undergoing an IPO process on the Sci-Tech Innovation Board, revealing a significant reduction in dedicated R&D personnel and a decrease in fundraising amount from 18.93 billion to 11.85 billion [1][5]. Group 1: R&D Personnel Changes - The number of dedicated R&D personnel at Baiaosaitu has drastically decreased from 58 at the end of 2022 to 5 by the end of 2024 [1][3]. - The total number of R&D personnel, including both dedicated and part-time, has also declined from 627 in 2022 to 337 in 2024 [3][4]. - The company has clarified that all personnel involved in innovative drug R&D are dedicated, while those in preclinical CRO services are part-time, aligning with industry norms [4]. Group 2: Fundraising Adjustments - The company has revised its fundraising target down to 11.85 billion, with allocations for various projects including early drug development services and antibody drug research [5]. - The initial fundraising amount was set at 18.93 billion, with the same project allocations, indicating a significant reduction of over 7 billion [5]. - The adjustments in fundraising may reflect changes in the company's operational status or market conditions, necessitating a reassessment of funding needs [5]. Group 3: Financial Performance - Baiaosaitu is projected to turn a profit in 2024 after consecutive years of losses, with revenues increasing from approximately 5.34 billion in 2022 to 9.8 billion in 2024 [5]. - The net profit attributable to the company is expected to shift from losses of 6.02 billion and 3.83 billion in 2022 and 2023, respectively, to a profit of approximately 335.42 million in 2024 [5].